Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab (Zytux) for diffuse cutaneous systemic sclerosis
IRCT2016022126686N1Phase 3Completed
- Sponsor
- AryoGen Biopharma
- Start
- Jul 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3 trial of rituximab in systemic sclerosis (SSc), sponsored by AryoGen Biopharma. Started Jul 2016; status: completed.
02
Drugs
rituximab
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on IRCT2016022126686N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT2016022126686N1.